These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33905669)

  • 1. Insights into oral bioavailability enhancement of therapeutic herbal constituents by cytochrome P450 3A inhibition.
    Chen J; Liu J; Huang Y; Li R; Ma C; Zhang B; Wu F; Yu W; Zuo X; Liang Y; Wang Q
    Drug Metab Rev; 2021 Nov; 53(4):491-507. PubMed ID: 33905669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening and verification of CYP3A4 inhibitors from Bushen-Yizhi formula to enhance the bioavailability of osthole in rat plasma.
    Liu JM; Chen JM; Lin MJ; Wu FC; Ma CR; Zuo X; Yu WQ; Huang MJ; Fang JS; Li WR; Wang Q; Liang Y
    J Ethnopharmacol; 2022 Jan; 282():114643. PubMed ID: 34534597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.
    van Waterschoot RA; Schinkel AH
    Pharmacol Rev; 2011 Jun; 63(2):390-410. PubMed ID: 21490128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice.
    Loos NHC; Martins MLF; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2023 May; 20(5):2477-2489. PubMed ID: 36976574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDR- and CYP3A4-mediated drug-herbal interactions.
    Pal D; Mitra AK
    Life Sci; 2006 Mar; 78(18):2131-45. PubMed ID: 16442130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.
    Kim SB; Yoon IS; Kim KS; Cho SJ; Kim YS; Cho HJ; Chung SJ; Chong S; Kim DD
    Planta Med; 2014 May; 80(7):561-7. PubMed ID: 24710899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors.
    Brantley SJ; Graf TN; Oberlies NH; Paine MF
    Drug Metab Dispos; 2013 Sep; 41(9):1662-70. PubMed ID: 23801821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous evaluation of substrate-dependent CYP3A inhibition using a CYP3A probe substrates cocktail.
    Lee E; Shon JC; Liu KH
    Biopharm Drug Dispos; 2016 Sep; 37(6):366-72. PubMed ID: 27323294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition.
    Zhao G; Huang J; Xue K; Si L; Li G
    Eur J Pharm Sci; 2013 Nov; 50(3-4):429-39. PubMed ID: 23981337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
    van Waterschoot RA; Lagas JS; Wagenaar E; van der Kruijssen CM; van Herwaarden AE; Song JY; Rooswinkel RW; van Tellingen O; Rosing H; Beijnen JH; Schinkel AH
    Cancer Res; 2009 Dec; 69(23):8996-9002. PubMed ID: 19920203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
    Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
    J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents.
    Ramasamy S; Kiew LV; Chung LY
    Molecules; 2014 Feb; 19(2):2588-601. PubMed ID: 24566323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
    Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
    J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Cryopreserved Human Intestinal Mucosa and Cryopreserved Human Enterocytes in the Evaluation of Herb-Drug Interactions: Evaluation of CYP3A Inhibitory Potential of Grapefruit Juice and Commercial Formulations of Twenty-Nine Herbal Supplements.
    Loretz C; Ho MD; Alam N; Mitchell W; Li AP
    Drug Metab Dispos; 2020 Oct; 48(10):1084-1091. PubMed ID: 32719085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo inhibition of CYP3A-mediated midazolam metabolism by anchusan in rats.
    Saito Y; Nishimura Y; Kurata N; Iwase M; Aoki K; Yasuhara H
    J Pharmacol Sci; 2011; 115(3):399-407. PubMed ID: 21358120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
    Zhou SF
    Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
    van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
    Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
    van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.